![novamind logo novamind logo](https://psychedelicspotlight.com/wp-content/uploads/2021/01/Mydecine-Innovations-Group-Josh-Bartch-495x400.png)
Tickets for this first-of-its-kind gathering are still available here.Pursuant to the Transaction, Numinus acquired all of the common shares of Novamind ("Novamind Shares") and the holders of Novamind Shares have received 0.84 (the "Exchange Ratio") of a common share of Numinus (each a "Numinus Share") for each Novamind Share held. To hear more about the important and fascinating scientific advances and meet face-to-face with some of this nascent industry’s professionals & market leaders, join us at the Benzinga Psychedelics Capital Conference on Apat the Fontainebleau Miami Beach where we are bringing together leaders of the largest publicly-traded Psychedelics companies with investors from across North America.
![novamind logo novamind logo](https://i.pinimg.com/originals/77/8a/55/778a55def68e62cb454ec31b7af2c53d.png)
#Novamind logo full#
But, who is the real Kevin O'Leary? Read the full story…
#Novamind logo tv#
Wonderful, the Canadian investor of Irish heritage is well known in the finance space and as a TV personality. Whether you're into finances or just a fan of Shark Tank, chances are you know who Kevin O’Leary is. Read the full story… 'Psychedelics Companies Are Onto Something Extraordinary,' Says Kevin O'Leary: Meet Our Keynote Speakers (OTC: IWINF), an herbal supplement formulator and leader in the nutrition industry at the forefront of the "psychedelics renaissance." Klee Irwin serves as CEO and chairman of Irwin Naturals and director of Quantum Gravity Research, a non-profit research institute he founded in 2009. Meet the person behind Irwin Naturals Inc. Klee Irwin Of Irwin Naturals At The Forefront Of 'Psychedelics Renaissance': Meet Our Keynote Speakers (OTC: ALID) has successfully filed for a full patent regarding “Dosing regimes of pharmaceutical and nutraceutical mushroom and cannabis compositions and their use to treat CNS disorders and improve mental health." Read the full story… Files Full Psilocybin Patent For Psilonex To Treat Central Nervous System DisordersĪllied Corp.
#Novamind logo trial#
(OTC: NVMDF) has been selected by Mind Medicine, Inc. (NASDAQ: MNMD) to host a Phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults. Read the full story… Novamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment The bill also proposes relying on current cannabis regulatory systems to track psychedelic mushrooms, reported Marijuana Moment. Read the full story… Washington State Legislature Proposes $200K To Fund Psilocybin ResearchĪ new budget bill with a proposal to earmark $200,000 for researching the possibility of legalizing psilocybin services in Washington State was filed by the State legislature on Thursday. (OTC: WSNAF) have received a full written response from the Food and Drug Administration regarding their pre-investigational new drug meeting for the novel therapy and proprietary protocol of SANA-013 for the treatment of traumatic brain injury-related major depressive disorder. Read the full story… Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD (OTC: MCURF), a mental health and wellness company working in the psychedelics sector, announced that a special committee its board of directors concluded a review process and has determined that the capital required to continue the Company's business plan is unlikely to be found under the current and foreseeable market conditions.
![novamind logo novamind logo](https://www.novamind.gmbh/images/banner/bannerImg2.jpg)
Mind Cure Health Is Shutting Down All Operations, Citing Lack Of Funds To Move Forward